These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 1395069

  • 1. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.
    van der Lely AJ, Harris AG, Lamberts SW.
    Clin Endocrinol (Oxf); 1992 Aug; 37(2):181-5. PubMed ID: 1395069
    [Abstract] [Full Text] [Related]

  • 2. Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue.
    Yang IM, Woo JT, Kim SW, Kim JW, Kim YS, Choi YK.
    Clin Endocrinol (Oxf); 1995 Mar; 42(3):295-301. PubMed ID: 7758235
    [Abstract] [Full Text] [Related]

  • 3. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
    [Abstract] [Full Text] [Related]

  • 4. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.
    Lamberts SW, Zweens M, Klijn JG, van Vroonhoven CC, Stefanko SZ, Del Pozo E.
    Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin?
    Riedel M, Günther T, von zur Mühlen A, Brabant G.
    Clin Endocrinol (Oxf); 1992 Sep; 37(3):233-9. PubMed ID: 1358484
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly.
    Arihara Z, Sakurai K, Yamashita R, Niitsuma S, Ueno T, Yamamura N, Yamada S, Inoshita N, Takahashi K.
    Tohoku J Exp Med; 2014 Oct; 234(2):129-35. PubMed ID: 25253414
    [Abstract] [Full Text] [Related]

  • 10. Bioactive GH-like immunoglobulins G in active acromegaly: response to long-term treatment with bromocriptine.
    Campino C, Szecowka J, Lopez JM, Seron-Ferre M.
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):111-6. PubMed ID: 7641402
    [Abstract] [Full Text] [Related]

  • 11. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study.
    Fredstorp L, Kutz K, Werner S.
    Clin Endocrinol (Oxf); 1994 Jul; 41(1):103-8. PubMed ID: 8050122
    [Abstract] [Full Text] [Related]

  • 12. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
    Jenkins PJ, Emery M, Howling SJ, Evanson J, Besser GM, Monson JP.
    Horm Res; 2004 Jul; 62(5):227-32. PubMed ID: 15477693
    [Abstract] [Full Text] [Related]

  • 13. Octreotide as primary therapy for acromegaly.
    Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL.
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [Abstract] [Full Text] [Related]

  • 14. [Response of growth hormone to sandostatin and bromocriptine and prognostic value of prolactin levels in serum and thyroliberin test in patients with active acromegaly].
    Gasińska T, Nowak S.
    Endokrynol Pol; 1993 Sep; 44(4):455-65. PubMed ID: 8055814
    [Abstract] [Full Text] [Related]

  • 15. Desensitization to somatostatin analogue (Octreotide) observed in a patient with acromegaly.
    Haraguchi K, Ohtaka M, Takazawa K, Endo T, Onaya T.
    Endocr J; 1995 Apr; 42(2):295-300. PubMed ID: 7627275
    [Abstract] [Full Text] [Related]

  • 16. A close correlation between the inhibitory effects of insulin-like growth factor-I and SMS 201-995 on growth hormone release by acromegalic pituitary tumours in vitro and in vivo.
    Lamberts SW, van Koetsveld P, Hofland L.
    Clin Endocrinol (Oxf); 1989 Oct; 31(4):401-10. PubMed ID: 2627746
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of GH paradoxical responses to TRH and LHRH in acromegalic patients during long-term treatment with octreotide.
    Merola B, Colao A, Cataldi M, Rossi E, Selleri A, Briganti F, Schettini G, Bellastella A, Lombardi G.
    Horm Res; 1992 Oct; 37(1-2):18-22. PubMed ID: 1398471
    [Abstract] [Full Text] [Related]

  • 18. Differential response to aminergic stimuli and biological behavior of growth hormone secreting pituitary adenomas.
    Fanghanel G, Larraza O, Villalobos M, Fanghanel L, Velasco M, Velasco F.
    Can J Neurol Sci; 1990 Feb; 17(1):78-82. PubMed ID: 2107017
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY, Weissberger AJ, Marbach P, Lazarus L.
    Ann Intern Med; 1990 Feb 01; 112(3):173-81. PubMed ID: 2404445
    [Abstract] [Full Text] [Related]

  • 20. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
    Hunter SJ, Shaw JA, Lee KO, Wood PJ, Atkinson AB, Bevan JS.
    Clin Endocrinol (Oxf); 1999 Feb 01; 50(2):245-51. PubMed ID: 10396369
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.